Decreased survival among lung cancer patients with co-morbid tuberculosis and diabetes by Shwn-Huey Shieh et al.
Shieh et al. BMC Cancer 2012, 12:174
http://www.biomedcentral.com/1471-2407/12/174RESEARCH ARTICLE Open AccessDecreased survival among lung cancer patients
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Shwn-Huey Shieh1,2, Janice C Probst3, Fung-Chang Sung4,5, Wen-Chen Tsai1, Ya-Shin Li6 and Chih-Yi Chen7,8*Abstract
Background: Comorbid conditions influence the survival of cancer patients. This study evaluated the influence of
comorbidity on survival among lung cancer patients.
Methods: The authors evaluated the medical records of 1111 lung cancer patients of a medical center in Taiwan.
Days of survival were calculated for each patient and mortality hazard ratios were estimated for associations with
demographic status, comorbidity and cancer stage at diagnosis.
Results: On average, the survival time was slightly longer among women than among men (838 ± 689 vs.
749 ± 654 days, p= 0.050). Survival days increased with age (from 580 ± 526 [≤ 50 years] to 803 ± 693 [≥ 71 years]
days, p= 0.020) and decreased with stage (from 1224 ± 656 [stage I] to 489 ± 536 [stage IV] days, p< 0.001). Younger
patients were more likely to be diagnosed with lung cancer at a late stage. Compared with lung cancer patients
without tuberculosis, those with tuberculosis had a significantly shorter average survival duration (584 vs. 791 days,
p= 0.002) and a higher mortality hazard ratio (1.30, 95% CI: 1.03 - 1.65). A similar trend was observed in lung cancer
patients with diabetes.
Conclusions: Lung cancer patients with comorbid tuberculosis or diabetes are at an elevated risk of mortality.
These patients deserve greater attention while undergoing cancer treatment.
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Cancer is a highly complicated disease. Cancer survival
mainly depends on patient characteristics, the histology
and pathology of the tumor, stage at diagnosis, host-
tumor interaction, and comorbidities. Comorbidity has
an inherent influence on each patient’s initial treatment
and the treatment effectiveness of patient care. Previous
studies have demonstrated that less aggressive treatment
is given to patients with breast cancer, prostate cancer,
lymphoma, or lung cancer who have specific existing
comorbidities [1-6]. Several diseases such as hyperten-
sion, ischemic heart disease, cerebrovascular disease,
chronic obstructive pulmonary disease (COPD), and dia-
betes mellitus (DM) are considered to have a significant
influence on the survival of cancer patients [2,7-10].* Correspondence: micc@www.cmuh.org.tw
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reproduction in any medium, provided the orIn the case of lung cancer patients, pulmonary and
cardiovascular function may have a significant impact on
survival [2,11-14]. Elderly patients with Stage I or II lung
cancer are less likely to receive surgery than younger
patients [13]. Patients with COPD, cardiovascular dis-
ease, or DM comorbidity also have a lower resection rate
[13]. Janssen-Heijnen et al. reported that the morbidity
and mortality of non-small cell lung cancer (NSCLC)
patients following resection are associated with poor
pulmonary function or cardiovascular disease [2]. Older
NSCLC patients have a higher prevalence of comorbid
cardiovascular disease or COPD, which may cause add-
itional morbidity and reduce their survival. Battafarano
et al. indicated that NSCLC patients with comorbidity
have a two-fold increased risk of death compared with
patients without comorbidity [11].
The presence of multiple comorbid diseases is com-
mon among lung cancer patients, with 22.1% of patients
having five or more comorbid diseases, 54.3% having
three or more, and 88.3% having one or more [14-16].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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COPD, and DM are the most common comorbidities
associated with a reduced survival among patients with
lung cancer [14]. They also identified that comorbidity is
important for predicting the survival of both localized
and advanced lung cancer [16].
The symptoms of lung cancer can be masked by the
symptoms of comorbid diseases such as chronic bron-
chitis, COPD, TB, DM, hypertension (HT), or even heart
disease [15,17,18]. Patients with comorbid diseases may
ignore symptoms or delay reporting them to a physician,
because the symptoms of lung cancer are often confused
with those of comorbid diseases. Comorbid diseases may
exert direct effects on the host immune system and re-
duce the duration of survival, and are thus among the
most important factors for determining lung cancer sur-
vival [19,20].
The objective of this study was to investigate the influ-
ence of comorbidity on the survival of patients with lung
cancer. Furthermore, we presented data showing the
associations between selected comorbid diseases (TB,
DM, HT, COPD, and other cancer [OC]) and survival.
Materials and methods
Sample
Data on the care of 1410 patients newly diagnosed with
histologically confirmed lung cancer between October
1997 and December 2004 at a medical center in central
Taiwan were extracted from the medical records of 2516
lung cancer patients by three trained medical nurses.
Group I included all lung cancer patients with resectable
tumors (n = 626) who had received surgery at the De-
partment of Thoracic Surgery. Group II comprised 784
patients with late-stage lung cancer who were randomly
selected from 1890 patients cared for at the Depart-
ments of Chest Medicine and Radiotherapy. There were
no significant differences between the 784 randomly
selected patients and those not selected in terms of age
(p= 0.309) or sex (p= 0.804).
Among the 1410 patients in groups I and II, 299 were
excluded from the analysis because they had incomplete
baseline information (for example, missing personal ID
or unknown cancer stage), metastatic cancer from other
organs or postoperative deaths. The remaining 1111
patients were included in the data analysis. This study




The number of days lived after the initial diagnosis was
recorded. Patients’ vital status information was obtained
from the official death registry. Patients were followed
for more than 7 years or until deceased.Comorbidity
Comorbidity was the disease present at the time of lung
cancer diagnosis. We adopted the method developed by
Charlson et al. to select comorbidities with potential as-
sociation with lung cancer survival. These were OC, TB,
DM, HT, and COPD [21].
Stage of the disease
The stage at diagnosis of each lung cancer case was
defined in accordance with the classification outlined in
the American Joint Committee on Cancer’s Cancer Sta-
ging Manual [22]. In Stage I, the cancer is in the lung
only, with normal tissue around the tumor. In Stage II,
the cancer has spread to nearby lymph nodes or the
chest wall, diaphragm, mediastinal pleura, or parietal
pericardium. In Stage III, the cancer has either spread to
the lymph nodes in the mediastinum (N2; Stage IIIa) or
to the lymph nodes on the opposite side of the chest or
in the lower neck (N3; Stage IIIb). Stage III is locally
advanced lung cancer. For the purpose of this study,
patients with Stage IIIa or IIIb lung cancer are combined
into a single group. In Stage IV, the cancer has spread to
other parts of the body or to another lobe of the lungs.
A physician checked the pathology or cytology reports
and the clinical image studies to confirm the tumor
stage diagnosis.
Control variables
Patients’ demographic characteristics (age, sex, religion,
education, marital status, and occupation) with implica-
tions for survival were controlled for in the multivariate
analyses.
Data analysis
Data analyses first used descriptive statistical analyses to
identify the mean, median and interquartile ranges of
survival duration by sociodemographic status, comorbid-
ity and cancer stage at diagnosis. Survival duration was
compared between men and women, among age groups
(≤ 50, 51–60, 61–70 and ≥ 71 years), other demographic
variables, among patients with and without the selected
comorbidity (OC, TB, COPD, DM and HT), and among
lung cancer stages. Mean days of survival were also esti-
mated to evaluate the interactions between comorbid-
ities and cancer stages. Multivariate Cox proportional
hazards regression was used to compute the adjusted
lung cancer mortality hazard ratios (HR) and 95% confi-
dence intervals (CI). Lung cancer mortality HRs were
calculated separately for men and women, different age
groups, patients with or without a specific comorbidity
and different cancer stages. We also used a Kaplan–
Meier model to compare patient survival rates between
those with and without a comorbidity that was signifi-
cantly associated with the duration of survival. Analyses
Table 1 Means, medians and interquartile ranges of survival days in patients with lung cancer by patient
characteristics, co-morbidity and stage of disease
Criteria N= 1111 Survival Days P-value for
meansn % Median 25th - 75th Mean± SD
Overall 1111 (100) 624 205 - 1190 772 ± 665
Age
≤ 50 94 (8.5) 419 188 - 864 580 ± 526 0.020
51 - 60 155 (14.0) 597 234 - 1039 738 ± 641
61 - 70 290 (26.1) 699 244 - 1228 792 ± 651
≥ 71 572 (51.5) 654 187 - 1268 803 ± 693
Gender
Male 822 (74.0) 596 188 - 1152 749 ± 654 0.050
Female 289 (26.0) 711 259 - 1279 838 ± 689
Marital Status
Married 964 (88.1) 626 216 - 1200 780 ± 666 0.112
Single (included divorce) 130 (11.9) 529 123 - 971 682 ± 636
Education
< Junior high 654 (63.3) 556 185 - 1187 756 ± 681 0.397
Junior high 137 (13.3) 647 211 - 1163 751 ± 611
Senior high 171 (16.6) 697 271 - 1287 842 ± 681
≥ College 71 (6.9) 528 201 - 1115 707 ± 623
Religion
No 294 (28.0) 651 182 - 1163 763 ± 662 0.847
Yes 755 (72.0) 615 211 - 1193 772 ± 666
Occupation
Work 323 (30.0) 554 188 - 1122 744 ± 662 0.378
Retired 296 (27.5) 555 177 - 1170 743 ± 672
Not work 457 (42.5) 715 233 - 1202 801 ± 654
Comorbidity
Other cancer
No 1031 (94.2) 606 201 - 1180 764 ± 666 0.116
Yes 64 (5.8) 813 350 - 1376 898 ± 643
Tuberculosis
No 989 (90.3) 653 220 - 1206 791 ± 667 0.002
Yes 106 (9.7) 364 107 - 856 584 ± 612
COPD
No 1040 (95.0) 614 206 - 1176 765 ± 662 0.162
Yes 55 (5.0) 863 317 - 1353 894 ± 714
Diabetes
No 967 (88.3) 651 220 - 1220 794 ± 670 0.001
Yes 128 (11.7) 427 134 - 929 600 ± 601
Hypertension
No 808 (73.8) 654 220 - 1219 788 ± 660 0.178
Yes 287 (26.2) >546 169 - 1122 726 ± 677
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Table 1 Means, medians and interquartile ranges of survival days in patients with lung cancer by patient
characteristics, co-morbidity and stage of disease (Continued)
Stage
I 216 (19.4) 1164 743 - 1681 1224± 656 <0.001
II 106 (9.5) 913 546 - 1498 1045± 674
III 406 (36.5) 555 220 - 1073 727 ± 622
IV 383 (34.5) 273 94 - 723 489 ± 536
COPD: chronic obstructive pulmonary disease.
Table 2 Baseline prevalence of comorbidity among lung
cancer patients and mean survival days by comorbidity
and stage of lung cancer at diagnosis
Comorbidity Stage P-
valueI II III IV
N= 214 N=104 N=399 N=378
% Mean % Mean % Mean % Mean
Other cancer
No 91.6 1235 96.2 1072 94.7 718 94.4 467 -
Yes 8.4 1157 3.8 334 5.3 829 5.6 853 0.093
Tuberculosis
No 92.5 1247 89.4 1075 90.2 743 89.4 500 -
Yes 7.5 1002 10.6 774 9.8 553 10.6 395 0.004
COPD
No 92.1 1213 94.2 1038 95.5 726 96.3 491 -
Yes 7.9 1408 5.8 1123 4.5 685 3.7 435 <0.001
Diabetes
No 86.9 1280 90.4 1065 88.7 752 88.1 492 -
Yes 13.1 889 9.6 836 11.3 503 11.9 466 0.008
Hypertension
No 70.1 1209 77.9 1111 75.4 757 73.0 498 -
Yes 29.9 1275 22.1 806 24.6 622 27.0 465 <0.001
Mean: Average of survival days.
COPD: chronic obstructive pulmonary disease.
Missing data: 16 cases.
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9.1, SAS Institute Inc., Cary, NC).
Results
Comparison of survival duration
The patients included in the analysis were mostly male,
elderly, and married. Most patients had a low educa-
tional attainment and a high proportion of religious af-
filiation (Table 1). Overall, the mean survival duration
was 772 ± 665 days, with a median of 624 days and inter-
quartile range of 205–1190 days. Survival medians were
consistently lower than survival means for all investi-
gated variables. Survival duration was longer in women
than in men, and increased with age, with mean from
580 ± 526 days for ≤ 50 years group to 803 ± 693 days
for ≥ 71 years group (p= 0.020). Survival duration was
not significantly associated with education level, religion
or job status. Table 1 also shows that almost half the
patients had at least one comorbid disease at baseline.
The most prevalent comorbidity was HT (26.2%), fol-
lowed by DM (11.7%), TB (9.7%), OC (5.8%) and COPD
(5.0%). On average, patients with comorbid OC or
COPD had a longer duration of survival, but this was
not a statistically significant difference. Those with
comorbid tuberculosis (p = 0.002), diabetes (p = 0.001) or
hypertension (p = 0.178) had a shorter duration of sur-
vival. Patient survival duration decreased with advancing
cancer stage, from an average of 1224 days for those
diagnosed with stage I to 489 days for those diagnosed
with stage IV cancer.
Survival duration by comorbidity and cancer stage
Table 2 shows the mean survival duration for lung can-
cer patients by comorbidity and cancer stage. In general,
the mean survival duration decreased with advancing
cancer stage. Patients with a comorbidity tended to have
a shorter survival duration, except for those with comor-
bid COPD or HT who were diagnosed with lung cancer
at an early stage. On average, patients with comorbid TB
or DM had a shorter survival duration than patients
without the corresponding diseases among all stages.
The Kaplan–Meier analysis showed that 7-year survival
rates were 11% lower for patients with TB than forpatients without TB (10% vs. 21%) (Figure 1) and 7% less
for patients with DM than for patients without DM
(14% vs. 21%) (Figure 2).
Mortality hazard ratio
The results of the multivariate Cox proportional hazards
analysis shows that men were at higher risk of death
than women (HR= 1.44, 95% CI = 1.20–1.72, Table 3).
The HRs were not significantly different among age
groups. Patients with comorbid TB had a HR of 1.30
(95% CI = 1.03–1.65). Those with comorbid DM also had
a higher risk of death (HR= 1.44, 95% CI = 1.15–1.80)
during the observation period. Patients with comorbid
OC, COPD or HT did not have a higher risk of death
Log-Rank test: P = 0.02 
Figure 1 The comparison of survival time between lung cancer patient with or without TB.
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The adjusted analysis showed that the stage at diagnosis
had a significant association with survival. Using Stage I
as the reference, the risk of death was markedly higher
among patients diagnosed at advanced cancer stages
(Stage II: HR =1.85, 95% CI = 1.30–2.61; Stage III: HR=
3.35, 95% CI = 2.57–4.35; Stage IV: HR= 5.63, 95% CI =
4.32–7.33).Figure 2 The comparison of survival time between lung cancer patienDiscussion
This study examined how patient characteristics and
selected comorbidities are associated with survival for
patients with lung cancer. Patients with comorbid TB or
DM had a reduced duration of survival, and a higher
mortality hazard. Younger patients had a shorter survival
duration than older patients, a phenomenon has not
been previously reported.Log rank Test: P=0.002 
t with or without DM.
Table 3 Mortality rate and multivariable Cox proportional hazards regression model measured hazard ratio (HR) and
95% confidence interval (CI) of mortality by demographic status, co-morbidity and stage of lung cancer
Variables N Death Person-days Mortality rate Rate ratio (95%CI) HRs* (95% CI) p-value
Overall 1111 738 857762 0.86
Gender
Male 822 565 615638 0.92 1.28 (1.08-1.52) 1.44 (1.20-1.72) <0.001
Female 289 173 242124 0.71 1.00 1.00
Age, years
≤ 50 94 68 54514 1.25 1.47 (1.14-1.90) 1.29 (0.99-1.70) 0.064
51 - 60 155 98 114428 0.86 1.01 (0.81-1.26) 0.89 (0.71-1.12) 0.328
61 - 70 290 183 229726 0.80 0.94 (0.79-1.12) 1.00 (0.83-1.20) 0.994
≥ 71 572 389 459094 0.85 1.00 1.00
Comorbidity
Other Cancer
No 1031 690 787641 0.88 1.00 1.00
Yes 64 38 57496 0.66 0.75 (0.54-1.05) 0.77 (0.55-1.07) 0.124
Tuberculosis
No 989 649 783186 0.83 1.00 1.00
Yes 106 79 61951 1.28 1.54 (1.22-1.94) 1.30 (1.03-1.65) 0.030
COPD
No 1040 696 795978 0.87 1.00 1.00
Yes 55 32 49159 0.65 0.74 (0.52-1.06) 0.97 (0.67-1.38) 0.848
Diabetes
No 967 633 768281 0.82 1.00 1.00
Yes 128 95 76856 1.24 1.50 (1.21-1.86) 1.44 (1.15-1.80) 0.002
Hypertension
No 808 534 636661 0.84 1.00 1.00
Yes 287 194 208476 0.93 1.11 (0.94-1.31) 1.07 (0.90-1.27) 0.453
Stage
I 216 73 264485 0.28 1.00 1.00
II 106 60 110785 0.54 1.96 (1.39-2.76) 1.85 (1.30-2.61) 0.001
III 406 289 295328 0.98 3.55 (2.74-4.58) 3.35 (2.57-4.35) <0.001
IV 383 316 187164 1.69 6.12 (4.74-7.89) 5.63 (4.32-7.33) <0.001
p for trend <0.001
COPD: chronic obstructive pulmonary disease.
* Adjusted Hazard Ratios, obtained with statistical adjustment for all the variables listed in this table.
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characteristics such as age, sex, marital status, and edu-
cation are important factors associated with cancer sur-
vival [13,17,23-26]. We found sex to be significantly
associated with survival in the multivariate analysis
(Table 3). Men had a shorter survival duration than
women and an approximately 44% increased mortality
hazard. This result is consistent with other studies
[16,27,28]. It is generally recognized that lung cancer
survival among women is far better than that among
men [27,28]. Lung cancer is biologically different in men
and women. The biological characteristics andprognostic profiles of the tumor may also differ between
them [26-28]. Approximately only 4.0–9.0% of women
are smokers in Taiwan. Female patients are more likely
to have never smoked than male patients [29,30]. Tai-
wanese women are also more likely than men to present
with adenocarcinoma rather than squamous carcinoma
of the lung [31].
Education, religion, marital status, and occupation were
not found to be significantly related to survival in the
adjusted analysis. Several previous studies have found a
significant association between age and survival
[13,23,24,26]. We found that younger patients had a
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A further analysis using a contingency table of age by
stage showed that a greater proportion of younger patients
(≤ 50 years) than older patients had their lung cancer
diagnosed at a late stage (47.9% vs. 30.1% in stage IV)
(data not shown). This late detection is likely to explain
why the younger patients had a much shorter survival
duration than the oldest group of patients (580± 526 vs.
803 ± 693 days on average). Young patients are apparently
unaware of the importance of early detection. They are
also more likely to be heavy smokers [16,32].
The lung cancer survival duration was also found to
be determined by the stage of disease, tumor biology
and comorbidity. Comorbidity is not only an independ-
ent prognostic factor for surgical resection, but also im-
portant in host-resistance and host–tumor interaction,
and has a significant role in survival [2,11-13,19].
Only a few studies have investigated the association
between comorbidity and lung cancer survival. Tamme-
magi et al. and Battafarano et al. found support for the
hypothesis that comorbidity is inversely related to sur-
vival duration [11,14]. Several studies found that TB,
DM, OC, COPD and peripheral vascular disease may in-
dependently predict reduced survival duration [9,14].
Our study also found that lung cancer patients with
comorbid TB or DM have a shorter survival duration
across all stages of lung cancer. However, some other
studies have contradictory findings. Janssen-Heijnen
et al. reported that comorbidity was not a significant fac-
tor determining cancer survival [13]. Poorer survival
among patients with TB or DM, even with stage at initial
diagnosis held constant, may stem from less efficient
immunization, anti-tumor defense systems, and multiple
organ dysfunctions with these conditions. Poorer lung
function, physical performance status, and nutrition, as
well as lower immunization among lung cancer patients
with TB may influence the available treatment choices
[19,20]. Furthermore, the chronic cough caused by TB
may cause patients to be ignorant their lung cancer and
delay them from seeking medical treatment, thus influ-
encing their survival.
The current clinical evaluation of treatment effective-
ness and the care of lung cancer patients put more em-
phasis on cancer stage and tumor biology, while
ignoring other patient characteristics. Comorbidities
may influence the choice of treatment and treatment
side effects, which are associated with patient survival.
Therefore, physicians should carefully evaluate each
patient’s comorbidities. In the present study, 9.7% of the
lung cancer patients had TB. TB patients are at higher
risk of developing lung cancer. Yu et al. found that
patients with pulmonary TB are at 11-fold higher risk of
developing lung cancers than those without TB [33].
Therefore, it is necessary to examine the respiratorytract symptoms of patients with TB to screen for lung
cancer and improve their survival. DM is one of the
world’s major chronic diseases and leading causes of
death. DM patients have poor nutrition absorption, and
are at risk of higher glucose and immunization, which
may also lead to limited treatment choices and reduced
survival [2,7-10].
Conclusions
In conclusion, this study suggests that lung cancer
patients with comorbidity, particularly DM or TB de-
serve more attention while undergoing cancer treatment.
In addition, having a valid disease-specific instrument to
measure and classify the overall severity of comorbidity
is very important for improving the outcome of lung
cancer care, especially for long-term survival. This study
also observed shorter survival durations among young
patients. More attention should be devoted to these
patients, who may have had the disease diagnosed at a
late stage.
Our findings reflect the importance of public health in
reducing the prevalence of comorbidities and late diag-
nosis among lung cancer patients. However, the bio-
logical and/or appropriate therapeutic implications of
comorbidities for lung cancer have not been addressed
in this study. They remain important issues for future
study. Further investigations focusing on caring for lung
cancer patients with comorbid diseases such as TB or
DM are needed to provide direction for clinicians treat-
ing patients with comorbid conditions.
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